Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients

Antiviral Research

Volumn 100, Issue 1, 2013, Pages 114-119

  D'Avolio, Antonio ^a   De Nicolò, Amedeo ^a   Cusato, Jessica ^a   Ciancio, Alessia ^b   Boglione, Lucio ^a   Strona, Silvia ^b   Cariti, Giuseppe ^a   Troshina, Giulia ^b   Caviglia, Gian Paolo ^b   Smedile, Antonina ^b   Rizzetto, Mario ^b   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Adverse event; Anemia; HCV; ITPA; Ribavirin; Single nucleotide polymorphism

Indexed keywords

HEMOGLOBIN; INOSINE TRIPHOSPHATASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHOSPHATASE; RIBAVIRIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; INORGANIC PYROPHOSPHATASE; INOSINE TRIPHOSPHATE; ITPA PROTEIN, HUMAN; PEGINTERFERON;

ADULT; ALLELE; ARTICLE; CHROMOSOME 20; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; ADVERSE EVENT; ANEMIA; DRUG MONITORING; ENZYMOLOGY; GENETICS; HCV; HEPATITIS C VIRUS; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTER-QUARTILE RANGE; IQR; ITPA; MIDDLE AGED; PEG/IFN; RBV; SINGLE NUCLEOTIDE POLYMORPHISMS; SNPS; SUSTAINED VIROLOGICAL RESPONSE; SVR; TDM; TREATMENT OUTCOME; WILD TYPE; WT;

ADVERSE EVENT; ANEMIA; HAEMOGLOBIN; HB; HCV; HEPATITIS C VIRUS; INOSINE TRIPHOSPHATASE; INOSINE TRIPHOSPHATE; INTER-QUARTILE RANGE; IQR; ITP; ITPA; PEG/IFN; PEGYLATED INTERFERON; RBV; RIBAVIRIN; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISMS; SNPS; SUSTAINED VIROLOGICAL RESPONSE; SVR; TDM; THERAPEUTIC DRUG MONITORING; WILD TYPE; WT;

ADULT; ANEMIA; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PYROPHOSPHATASES; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84888183473     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.07.021     Document Type: Article

References (47)

1. D. Aguilar Marucco, D. Gonzalez de Requena, S. Bonora, C. Tettoni, M. Bonasso, T. De Blasi, A. D'Avolio, M. Sciandra, M. Siccardi, L. Baietto, L. Trentini, A. Sinicco, G. Cariti, and G. Di Perri The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon J. Antimicrob. Chemother. 61 2008 919 924 (Pubitemid 351426079)
2. J.M. Barrera, M. Bruguera, M.G. Ercilla, C. Gil, R. Celis, M.P. Gil, M. del Valle Onorato, J. Rodes, and A. Ordinas Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C Hepatology 21 1995 639 644
3. D. Breilh, J. Foucher, L. Castera, P. Trimoulet, S. Djabarouti, W. Merrouche, P. Couzigou, M.C. Saux, and V. de Ledinghen Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C Aliment. Pharmacol. Ther. 30 2009 487 494
4. G. Caviglia, A. D'Avolio, A. Ciancio, A. De Nicolò, L. Boglione, M. Abate, C. Rosso, A. Smedile, G. Cariti, and J. Cusato F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after 1 month of anti-HCV therapy Dig. Liver Dis. 44 2012 S42
5. A. D'Avolio, A. Ciancio, M. Siccardi, L. Baietto, M. Simiele, G. Cariti, A. Calcagno, A. Smedile, J. Cusato, S. Bonora, M. Rizzetto, and G. Di Perri Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4 Hepatology 54 2011 2279
6. A. D'Avolio, A. De Nicolo, M. Simiele, S. Turini, D. Agnesod, L. Boglione, J. Cusato, L. Baietto, G. Cariti, A. Calcagno, M. Sciandra, G. Di Perri, and S. Bonora Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients J. Pharm. Biomed. Anal. 66 2012 376 380
7. A. D'Avolio, A. Ciancio, M. Siccardi, A. Smedile, L. Baietto, M. Simiele, D.A. Marucco, G. Cariti, A. Calcagno, D.G. de Requena, M. Sciandra, J. Cusato, G. Troshina, S. Bonora, M. Rizzetto, and G. Di Perri Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment Ther. Drug Monit. 34 2012 165 170
8. A. D'Avolio, A. Ciancio, M. Siccardi, A. Smedile, M. Simiele, J. Cusato, L. Baietto, D.A. Marucco, G. Cariti, A. Calcagno, D.G. de Requena, M. Sciandra, G. Troshina, G.P. Caviglia, S. Bonora, M. Rizzetto, and G. Di Perri Negative predictive value of IL28B, SLC28A2 and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment Ther. Drug Monit. 34 2012 722 728
9. D'Avolio, A., Cusato, J., Calcagno, A., Di Perri, G., 2013. Estimating ribavirin plasma exposure: Genetics or therapeutic drug monitoring? J. Hepatol. 2013. pii: S0168-8278(13)00347-4.
10. L. De Franceschi, G. Fattovich, F. Turrini, K. Ayi, C. Brugnara, F. Manzato, F. Noventa, A.M. Stanzial, P. Solero, and R. Corrocher Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage Hepatology 31 2000 997 1004 (Pubitemid 30169949)
11. A. De Nicolò, J. Cusato, L. Boglione, A. Ciancio, A. Smedile, D. Agnesod, G. Cariti, M. Rizzetto, G. Di Perri, and A. D'Avolio P-21 Early ribavirin plasma concentrations as predictor of anemia onset after 1 month of anti-HCV therapy in ITPA stratified population Rev. Antiviral Ther. Infect. Dis. 3 2013 51
12. J. Fellay, A.J. Thompson, D. Ge, C.E. Gumbs, T.J. Urban, K.V. Shianna, L.D. Little, P. Qiu, A.H. Bertelsen, M. Watson, A. Warner, A.J. Muir, C. Brass, J. Albrecht, M. Sulkowski, J.G. McHutchison, and D.B. Goldstein ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C Nature 464 2010 405 408
13. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, F.L. Goncales Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, and J. Yu Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N. Engl. J. Med. 347 2002 975 982
14. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, T.J. Urban, E.L. Heinzen, P. Qiu, A.H. Bertelsen, A.J. Muir, M. Sulkowski, J.G. McHutchison, and D.B. Goldstein Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
15. J.E. Groopman, and L.M. Itri Chemotherapy-induced anemia in adults: incidence and treatment J. Natl Cancer Inst. 91 1999 1616 1634 (Pubitemid 29479929)
16. S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer Jr., D. Bernstein, M. Rizzetto, S. Zeuzem, P.J. Pockros, A. Lin, and A.M. Ackrill Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann. Intern. Med. 140 2004 346 355
17. C. Hezode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, T. Goeser, J.P. Bronowicki, M. Bourliere, S. Gharakhanian, L. Bengtsson, L. McNair, S. George, T. Kieffer, A. Kwong, R.S. Kauffman, J. Alam, J.M. Pawlotsky, and S. Zeuzem Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N. Engl. J. Med. 360 2009 1839 1850
18. Y. Hitomi, E.T. Cirulli, J. Fellay, J.G. McHutchison, A.J. Thompson, C.E. Gumbs, K.V. Shianna, T.J. Urban, and D.B. Goldstein Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by restoring adenylosuccinate synthase function Gastroenterology 140 2011 1314 1321
19. R. Kubota, T. Komiyama, N. Kumagai, M. Kimijima, K. Mitsuki, J. Uetake, F. Kaneko, S. Tsunematsu, and K. Tsuchimoto Optimal erythrocyte ribavirin level to reduce the risk of anemia and obtain an early virological response in patients with chronic hepatitis C caused by genotype 1b infection Hepat. Res. Treat. 2010 2010 495928
20. M. Kurosaki, Y. Tanaka, N. Nishida, N. Sakamoto, N. Enomoto, K. Matsuura, Y. Asahina, M. Nakagawa, M. Watanabe, M. Sakamoto, S. Maekawa, K. Tokunaga, M. Mizokami, and N. Izumi Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C J. Med. Virol. 85 2013 449 458
21. P.Y. Kwo, E.J. Lawitz, J. McCone, E.R. Schiff, J.M. Vierling, D. Pound, M.N. Davis, J.S. Galati, S.C. Gordon, N. Ravendhran, L. Rossaro, F.H. Anderson, I.M. Jacobson, R. Rubin, K. Koury, L.D. Pedicone, C.A. Brass, E. Chaudhri, and J.K. Albrecht Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
22. K. Lindahl, R. Schvarcz, A. Bruchfeld, and L. Stahle Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia J. Viral Hepat. 11 2004 84 87 (Pubitemid 38221622)
23. V. Loustaud-Ratti, S. Alain, A. Rousseau, I.F. Hubert, F.L. Sauvage, P. Marquet, F. Denis, F. Lunel, P. Cales, A. Lefebvre, A.L. Fauchais, E. Liozon, and E. Vidal Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C Hepatology 47 2008 1453 1461 (Pubitemid 351702729)
24. V. Loustaud-Ratti, P. Carrier, A. Rousseau, M. Maynard, G. Babany, S. Alain, C. Trepo, V. De Ledinghen, M. Bourliere, S. Pol, V. Di Martino, J.P. Zarski, A. Pinta, D. Sautereau, and P. Marquet Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment Dig. Liver Dis. 43 2011 850 855
25. R. Mac Nicholas, and S. Norris Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents Aliment. Pharmacol. Ther. 31 2010 929 937
26. M. Maynard, P. Pradat, M.C. Gagnieu, C. Souvignet, and C. Trepo Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients Antiviral Ther. 13 2008 607 611 (Pubitemid 352016724)
27. J.G. McHutchison, M.P. Manns, and D.L. Longo Definition and management of anemia in patients infected with hepatitis C virus Liver Int. 26 2006 389 398
28. J. Morello, S. Rodriguez-Novoa, I. Jimenez-Nacher, and V. Soriano Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C J. Antimicrob. Chemother. 62 2008 1174 1180
29. S. Naggie, N.I. Rallon, J.M. Benito, J. Morello, S. Rodriguez-Novoa, P.J. Clark, A.J. Thompson, K.V. Shianna, E. Vispo, J.G. McHutchison, D.B. Goldstein, and V. Soriano Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes J. Infect. Dis. 205 2012 376 383
30. H. Nomura, H. Tanimoto, E. Kajiwara, J. Shimono, T. Maruyama, N. Yamashita, M. Nagano, M. Higashi, T. Mukai, Y. Matsui, J. Hayashi, S. Kashiwagi, and H. Ishibashi Factors contributing to ribavirin-induced anemia J. Gastroenterol. Hepatol. 19 2004 1312 1317 (Pubitemid 39481767)
31. H. Ochi, T. Maekawa, H. Abe, Y. Hayashida, R. Nakano, M. Kubo, T. Tsunoda, C.N. Hayes, H. Kumada, Y. Nakamura, and K. Chayama ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy - a genome-wide study of Japanese HCV virus patients Gastroenterology 139 2010 1190 1197
32. C. Pedersen, A. Alsio, M. Lagging, N. Langeland, M. Farkkila, M.R. Buhl, K. Morch, J. Westin, P. Sangfelt, G. Norkrans, and P.B. Christensen Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection J. Viral Hepat. 18 2011 245 251
33. M. Rau, F. Stickel, S. Russmann, C. Manser, P. Becker, M. Weisskopf, J. Schmitt, M.T. Dill, J.F. Dufour, D. Moradpour, D. Semela, B. Mullhaupt, and A. Geier Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection J. Hepatol. 58 2013 669 675
34. A.L. Rendon, M. Nunez, M. Romero, P. Barreiro, L. Martin-Carbonero, J. Garcia-Samaniego, I. Jimenez-Nacher, J. Gonzalez-Lahoz, and V. Soriano Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients J. Acquir. Immune Defic. Syndr. 39 2005 401 405 (Pubitemid 41003783)
35. N. Sakamoto, Y. Tanaka, M. Nakagawa, H. Yatsuhashi, S. Nishiguchi, N. Enomoto, S. Azuma, Y. Nishimura-Sakurai, S. Kakinuma, N. Nishida, K. Tokunaga, M. Honda, K. Ito, M. Mizokami, and M. Watanabe ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C Hepatol. Res. 40 2010 1063 1071
36. M. Shipkova, K. Lorenz, M. Oellerich, E. Wieland, and N. von Ahsen Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population Clin. Chem. 52 2006 240 247 (Pubitemid 43185485)
37. M.S. Sulkowski, M.L. Shiffman, N.H. Afdhal, K.R. Reddy, J. McCone, W.M. Lee, S.K. Herrine, S.A. Harrison, F.F. Poordad, K. Koury, W. Deng, S. Noviello, L.D. Pedicone, C.A. Brass, J.K. Albrecht, and J.G. McHutchison Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate Gastroenterology 139 2010 1602 1611 1611 e1601
38. S. Sumi, A.M. Marinaki, M. Arenas, L. Fairbanks, M. Shobowale-Bakre, D.C. Rees, S.L. Thein, A. Ansari, J. Sanderson, R.A. De Abreu, H.A. Simmonds, and J.A. Duley Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency Hum. Genet. 111 2002 360 367 (Pubitemid 36075062)
39. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M.L. Abate, M. Bassendine, U. Spengler, G.J. Dore, E. Powell, S. Riordan, D. Sheridan, A. Smedile, V. Fragomeli, T. Muller, M. Bahlo, G.J. Stewart, D.R. Booth, and J. George IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat. Genet. 41 2009 1100 1104
40. F. Suzuki, Y. Suzuki, N. Akuta, H. Sezaki, M. Hirakawa, Y. Kawamura, T. Hosaka, M. Kobayashi, S. Saito, Y. Arase, K. Ikeda, K. Chayama, N. Kamatani, Y. Nakamura, Y. Miyakawa, and H. Kumada Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir Hepatology 53 2011 415 421
41. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, N. Sakamoto, M. Nakagawa, M. Korenaga, K. Hino, S. Hige, Y. Ito, E. Mita, E. Tanaka, S. Mochida, Y. Murawaki, M. Honda, A. Sakai, Y. Hiasa, S. Nishiguchi, A. Koike, I. Sakaida, M. Imamura, K. Ito, K. Yano, N. Masaki, F. Sugauchi, N. Izumi, K. Tokunaga, and M. Mizokami Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat. Genet. 41 2009 1105 1109
42. A.J. Thompson, J. Fellay, K. Patel, H.L. Tillmann, S. Naggie, D. Ge, T.J. Urban, K.V. Shianna, A.J. Muir, M.W. Fried, N.H. Afdhal, D.B. Goldstein, and J.G. McHutchison Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction Gastroenterology 139 2010 1181 1189
43. A.J. Thompson, A.J. Muir, M.S. Sulkowski, D. Ge, J. Fellay, K.V. Shianna, T. Urban, N.H. Afdhal, I.M. Jacobson, R. Esteban, F. Poordad, E.J. Lawitz, J. McCone, M.L. Shiffman, G.W. Galler, W.M. Lee, R. Reindollar, J.W. King, P.Y. Kwo, R.H. Ghalib, B. Freilich, L.M. Nyberg, S. Zeuzem, T. Poynard, D.M. Vock, K.S. Pieper, K. Patel, H.L. Tillmann, S. Noviello, K. Koury, L.D. Pedicone, C.A. Brass, J.K. Albrecht, D.B. Goldstein, and J.G. McHutchison Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 120-129 2010 e118
44. A.J. Thompson, R. Santoro, V. Piazzolla, P.J. Clark, S. Naggie, H.L. Tillmann, K. Patel, A.J. Muir, K.V. Shianna, L. Mottola, D. Petruzzellis, M. Romano, F. Sogari, D. Facciorusso, D.B. Goldstein, J.G. McHutchison, and A. Mangia Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR Hepatology 53 2010 389 395
45. A. Tsubota, Y. Hirose, N. Izumi, and H. Kumada Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection Br. J. Clin. Pharmacol. 55 2003 360 367 (Pubitemid 36535366)
46. L.G. van Vlerken, M.G. van Oijen, and K.J. van Erpecum Ribavirin concentration is a more important predictor of sustained viral response than anemia in hepatitis C patients Gastroenterology 140 2011 1693 1694
47. H. Van Vlierbergh, J.R. Delanghe, M. De Vos, and G. Leroux-Roel Factors influencing ribavirin-induced hemolysis J. Hepatol. 34 2001 911 916 (Pubitemid 32595192)